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Abstract
Introduction: Rheumatoid arthritis (RA) is now suspected to be driven by pathogenic Th17 cells that secrete
interleukin (IL)-17 and can be regulated by IL-4. A single-nucleotide polymorphism (SNP), I50V, in the coding region
of the human IL-4 receptor (IL-4R) is associated with rapid development of erosive disease in RA. The present study
was undertaken to determine whether this SNP renders the IL-4R less able to transduce signals that regulate IL-17
production.
Methods: Peripheral blood mononuclear cells were activated under Th17-stimulating conditions in the presence or
absence of IL-4, and IL-17 production was measured by both enzyme-linked immunosorbent assay (ELISA) and flow
cytometry. Serum IL-17 was also measured by ELISA. Paired comparisons were performed using the two-tailed t-
test. IL-4 receptor gene alleles were determined by polymerase chain reaction.
Results: In healthy individuals, IL-4 significantly inhibited IL-17 production by cells from subjects with the I/I
genotype (P = 0.0079) and the I/V genotype (P = 0.013), but not the V/V genotype (P > 0.05). In a cross-sectional
sample of patients with established RA, the magnitude of the in vitro effect of IL-4 was lower and was not
associated with a specific IL-4R allele. Serum IL-17 levels were higher in RA patients than in healthy individuals, as
was the percentage of CD4+ cells that produced IL-17.
Conclusions: These results indicate that an inherited polymorphism of the IL-4R controls the ability of the human
immune system to regulate the magnitude of IL-17 production. However, in established RA, this pattern may be
altered, possibly due to secondary effects of both RA itself as well as immunomodulatory medications. Ineffective
control of Th17 immune responses is a potential mechanism to explain why IL-4R is an important severity gene in
RA, but this issue will require careful study of a cohort of new-onset RA patients.
Introduction
Until recently, CD4+ lymphocytes were thought to con-
tain two distinct lineages of effector cells, the Th1 and
Th2 subsets that are defined by secretion of either inter-
feron (IFN)-g or interleukin (IL)-4. This paradigm has
been modified to now include a third CD4+ T-cell
population, the Th17 cells [1,2]. Th17 cells are critical
for autoimmune inflammation in a variety of murine
models of human disease, such as experimental autoim-
mune encephalomyelitis (EAE) and collagen-induced
arthritis (CIA) [3-5].
Unique mechanisms control the development of these
cells. The cytokines IL-6 and tumor growth factor
(TGF)-b are crucial for the generation of Th17 cells in
the mouse [6-8], while IL-1b, IL-6 and IL-23 induce and
maintain the differentiation of human Th17 cells [9,10].
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Accumulating evidence suggests that Th17 cells play a
central role in the development of human autoimmune
diseases, including RA, inflammatory bowel disease and
multiple sclerosis [11].
Th17 cell development and cytokine secretion are
downregulated in vitro by IFN-g and IL-4 produced by
Th1 and Th2 cells, respectively [1,2,12,13]. Understand-
ing the mechanisms of Th17 regulation in human dis-
ease is essential for the development of novel, targeted
therapies and to guide therapeutic decision-making.
Several findings suggest that the Th2 cytokine IL-4 and
its receptor may be of particular interest in the control of
Th17-induced inflammation. In mice, the genetic absence
of IL-4 leads to more severe arthritis in the CIA model
[14]. Conversely, dendritic cells transfected with a retro-
viral vector that drives expression of IL-4 reduced the
severity of CIA and suppressed IL-17 production in sec-
ondary responses to type II collagen [15,16]. Suppression
of IL-17 production by type II collagen-specific T cells
was seen early in CIA, but T cells from established late
CIA were refractory to inhibition of IL-17 production by
IL-4 [16]. Exosomes derived from IL-4-expressing den-
dritic cells were also found to be therapeutic in CIA [17].
In humans, a diminished response to IL-4 is thought
to contribute to autoimmune inflammation [18]. A sin-
gle-nucleotide polymorphism (SNP) in the coding region
of the IL-4R governs the presence of isoleucine (I) ver-
sus valine (V) at position 50 in the amino acid sequence.
This polymorphism in IL-4R is functionally important
because it affects the strength of signaling through the
receptor [19,20].
Additional evidence for a crucial role of IL-4 in regu-
lating human RA comes from a report of the effect of
IL-4 receptor gene (IL-4R) polymorphisms on the course
and severity of RA. Prots et al. [21] studied the role of
two IL-4R SNPs in RA susceptibility and severity in a
cohort of controls and RA patients with erosive disease.
In their study, each polymorphism was in Hardy-
Weinberg equilibrium, and IL-4R was not found to be
an RA susceptibility gene. The I50 and V50 alleles were
in an approximately 1:1 ratio in both the RA and con-
trol groups. Two years after the onset of disease 68% of
RA patients homozygous for the V50 allele had radio-
graphically visible bone erosion compared to 37% of the
patients homozygous for the I50 allele. Heterozygotes
had an intermediate level of radiographic severity. The
V50 homozygous patients demonstrated weaker signal-
ing through the IL-4R as measured by GATA-3 tran-
scription and IL-12R expression in cultured T cells [21].
A second polymorphism, located elsewhere in IL-4R, did
not control RA severity. These findings suggest that a
unique IL-4R polymorphism may predict disease out-
come in RA. Since tight control of the clinical activity of
RA substantially improves patient outcomes [22,23],
identification of patients who require early aggressive
treatment by genotyping for severity has the potential to
enhance patient care.
On the basis of these considerations, we hypothesized
that a hypofunctional IL-4R would allow unchecked
Th17 differentiation and Th17-driven inflammation. We
sought to show that Th17 cells derived from healthy
V50 homozygotes would be less susceptible to suppres-
sion of IL-17 production by IL-4 compared to I50
homozygotes or heterozygotes. We also undertook a
pilot cross-sectional study of patients with established
RA to assess the relationship between IL-4R genotype,
disease activity and regulation of IL-17 production
in vivo and in vitro. Our data indicate that deficiency in
regulation of IL-17 production is a possible mechanism
to explain the association of an IL-4R polymorphism
with RA severity.
Materials and methods
Study populations and clinical evaluation
Twenty patients with established RA and 26 healthy
individuals were enrolled in the study. The average age
of the healthy individuals was 40.6 years (range, 21 to
62 years), and this group included 12 females and 14
males. The characteristics of the RA patients are sum-
marized in Table S1 (Additional file 1). Health assess-
ment questionnaires were completed by each patient,
and disease activity scores were calculated on the basis
of a 28-joint count and a visual analogue scale. Thirty
milliliters of blood were collected from each subject.
Twenty milliliters were saved for cell culture, 5 ml were
saved for DNA isolation and genotyping and 5 ml were
saved for serum. All study participants provided written
informed consent. The research protocol was approved
by the University of Michigan Institutional Review
Board.
DNA isolation and genotyping
DNA was isolated from peripheral blood cells using the
Qiagen QIAmp Blood Midi kit (Qiagen, Chatsworth, CA,
USA) by a spin protocol according to manufacturer’s
instructions. Genotypes for I50V SNP of the IL-4R were
determined by allele-specific real-time polymerase chain
reaction (RT-PCR) using TaqMan Genotyping Assays
(Applied Biosystems, division of Life Technologies, Carls-
bad, CA, USA). The National Center for Biotechnology
Information SNP reference for the I50V allele is
rs1805010, and the nucleotide sequence surrounding the
probe is CTGTGTCTGCAGAGCCCACACG TGT[A/G]
TCCCTGAG AACAACGGAGGCGCGGG. RT-PCR was
performed for allelic discrimination using a quantitative
fluorescence measurement system.
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Cell culture
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized peripheral whole blood of RA
patients and healthy controls by gradient centrifugation
over Histopaque-1077 (Sigma, St. Louis, MO, USA). Cell
cultures were performed in RPMI 1066 medium (Lonza,
Basel, Switzerland) with 10% fetal bovine serum, 1%
penicillin G/1% streptomycin and 2% L-glutamine.
PBMCs were activated with Orthoclone OKT3
(anti-CD3, produced in the University of Michigan
Hybridoma Core) 1 μg/ml and either Th17-stimulating
conditions alone (IL-23, 10 ng/ml; IL-1b, 5 ng/ml; IL-6,
10 ng/ml) or Th17-stimulating conditions with the addi-
tion of IL-4 (50 ng/ml). Cells were left in culture for
96 hours. Supernatants were collected from each culture
condition and stored at -80°C for analysis by ELISA.
Surface and intracellular staining
On day 5 of culture, the cells were restimulated with
phorbol myristate acetate (5 ng/ml) and ionomycin
(500 ng/ml) for 1 hour prior to addition of brefeldin A
(10 μg/ml) for 5 more hours. The cells were washed and
1 × 106 cells per sample were used for staining. Cells
were first blocked with 20 μl of 10% human serum/10%
mouse serum in PBS at 4°C for 15 minutes. The cells
were surface-stained with antigen-presenting cell (APC)-
labeled mouse anti-human CD4 (BD Bioscience (Palo
Alto, CA, USA) or APC-conjugated mouse immunoglo-
bulin G1 (mIgG1) isotype control (Ebioscience, San
Diego, CA, USA), at 4°C for 30 minutes, washed twice
with cold 2% newborn calf serum/phosphate-buffered
saline (NCS/PBS) buffer and fixed overnight in 4% par-
aformaldehyde. The cells were then permeabilized with
0.5% saponin in 2% NCS/PBS. Intracellular cytokine
staining was performed using fluorescein isothiocyanate
(FITC)-labeled anti-human IFN-g (BD Bioscience)
and phycoerythrin (PE)-labeled anti-human IL-17A
(Ebioscience), or FITC-conjugated mIgG1 isotype con-
trol (Ebioscience) and PE-conjugated mouse IgG1 iso-
type control (Ancell, Bayport, MN, USA). Samples were
run on a BD Biosciences FACS Calibur flow cytometer
and analyzed by CellQuest Pro (BD Bioscience).
ELISA
Both culture supernatants and fresh sera were analyzed
by ELISA for IL-17A levels. Flat-bottomed, high binding,
96-well plates (Corning Costar, Lowell, MA, USA) were
coated overnight at 4°C with anti-human IL-17-purified
antibody (Ebioscience) diluted to 1:500 with 0.1 M car-
bonate buffer, pH 9.4. On day 2, the plates were washed
three times with 1 × PBS/0.05% Tween at 200 μl per
well and blocked using 200 μl of PBS with 10% fetal calf
serum per well for 2 hours. The plates were then
washed three times with 200 μl of 1 × PBS/0.05%
Tween per well. The standard curve was created in
duplicate starting with a concentration of 2,000 pg/ml
and serial twofold dilutions to 7.8 pg/ml. Supernatants
and sera were assayed in triplicate at 100 μl per well,
both undiluted and at a 1:5 dilution. The samples were
then refrigerated at 4°C overnight, after which they were
washed five times with 200 μl of 1 × PBS/0.05% Tween
per well. A secondary biotinylated anti-IL-17 antibody
and the detection reagent streptavidin horseradish per-
oxidase were added to each well and incubated at room
temperature for 2 hours. The plates were washed seven
times with 1 × PBS/0.05% Tween with 1-minute soaks
between washes. Tetramethylbenzidine 100 μl were
added to each well, and plates were kept in the dark at
room temperature for 10 to 30 minutes. Stop solution,
2 N H2SO4, was added to each well. ELISA plates were
read by a Synergy HT plate reader (Biotek, Winsooki,
VT, USA) and analyzed by KC4 software (Biotek).
Statistical analysis
The data were analyzed with GraphPad Prism version
4.02 software (GraphPad Software Inc., San Diego, CA,
USA). Paired comparisons were performed using a two-
tailed t-test. Values of P ≤ 0.05 were considered signifi-
cant. Dot plots were generated in CellQuest Pro.
Results
IL-17 production in culture supernatants
We measured IL-17 secretion by ELISA of lymphocyte
culture supernatants. In the healthy individuals there
was a significant increase in the IL-17 level after the
addition of Th17-stimulatory cytokines over baseline
T cell stimulation with anti-CD3 (P < 0.01), and there
was a significant decrease in the measured IL-17 level
with the addition of IL-4 to the Th17-stimulatory condi-
tions (Figure 1).
We then further examined these groups by specific
genotype. In the I/I genotype group, addition of IL-4 led
to a significant reduction in IL-17 production by cells
that had been stimulated under Th17 conditions (P <
0.01). There was also a significant reduction in IL-17
production after the addition of IL-4 to cells from the I/
V genotype group (P < 0.05). However, IL-4 was unable
to significantly reduce IL-17 production in cell cultures
from the V/V genotype group when the data were ana-
lyzed using paired comparisons (Figure 2A and 2B).
Cross-sectional pilot study of RA patients
Of the 20 RA patients (85% women and 15% men), 4
were homozygous for isoleucine, 6 were heterozygous
and 10 were homozygous for valine at amino acid 50 of
the IL-4R (Table S1 in Additional file 1). The mean dis-
ease activity score (DAS) for the patients with an I/I
genotype was 3.1, representing low disease activity.
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The mean DAS for the patients with the I/V genotype
was 3.9, or moderate disease activity, and for the
patients with the V/V genotype the mean DAS was 4.2,
or high to moderate disease activity. The differences
between these groups were not statistically significant,
but suggest a trend toward association of the V allele
with more active disease, notwithstanding the aggressive
treatment that these patients were receiving.
There was not a significant increase in IL-17 produc-
tion in RA patients in Th17-skewing conditions versus
culture with anti-CD3 alone (P = 0.13) (Figure S1 in
Additional file 1). IL-4 did suppress IL-17 production
in vitro, albeit not to the extent seen in healthy controls.
Comparing the RA groups, the extent of suppression of
IL-17 production by IL-4 was intermediate and appeared
to be similar among all genotype groups (Figure S2 in
Additional file 1).
Enumeration of Th17+ cells
We also performed intracellular staining of cultured
cells for both IL-17 and IFN-g and examined the sam-
ples by flow cytometry. A set of representative flow
cytometry histograms is shown in Figure 3 for each of
the healthy control group genotypes. There was a more
pronounced suppression of the percentage of IL-17+
cells in the I/I genotype culture, as shown in the top
row of Figure 3A, compared to the suppression of IL-17+
cells in the V/V genotype culture, shown in the bottom
row. In these cultures, the majority of IL-17+ cells were
CD4+, but some CD4-IL-17+ cells were also observed.
IL-4 likewise affected the expression of IL-17 by these
CD4- cells. Flow cytometry of cultured PBMCs activated
under Th17 conditions showed that RA patients gener-
ated a higher percentage of IL-17+ and IL-17+/IFNg+
(Th1/Th17) cells compared to controls (Figure 3B). A
large proportion of the Th17 cells in both healthy indivi-
duals and patients with RA are of dual Th17/Th1 lineage.
IL-4 generally reduced the number of IL-17+/IFNg+ cells
in parallel with reductions in the number of IL-17+/IFNg-
cells (data not shown).
IL-17 concentrations in serum
Consistent with in vitro generation of higher numbers of
Th17 cells from RA mononuclear cells, we also observed
higher serum IL-17 levels in the RA patients compared
to the healthy individuals (P = 0.05) (Figure 4). These
results, as well as the flow cytometry data summarized
in Figure 3, are consistent with a recent report that
documents expansion of the Th17 subset in RA patients
compared to healthy individuals [24].
Discussion
Several earlier studies supported a key role for IL-17 in
the pathogenesis of RA [25]. Determining the regulatory
mechanisms that could suppress Th17 cells might lead
to novel approaches to the treatment of RA. In this
study, we have examined the role of a single nucleotide
polymorphism in the IL-4R in the control of IL-17
production.
The results indicate that a polymorphism in IL-4R in
part controls production of IL-17 by Th17 cells cultured
from healthy individuals. Specifically, IL-4 significantly
inhibited IL-17 production by cells from subjects with
the I/I genotype (P = 0.0079) and the I/V genotype (P =
0.013), but not the V/V genotype. An earlier study
showed an association between two copies of the V50
allele and the rapid development of radiographic erosive
disease [21]. That report also identified functional effects
of the IL-4R polymorphism pertinent to Th1 and Th2
cells. With the recent accumulation of information
regarding Th17 cells and RA [25], demonstration of a
functional impact of the IL-4R polymorphism on IL-17
secretion provides further mechanistic insight that could
be pertinent to the genetic control of RA severity.
There were several limitations to our current study.
The healthy control and RA groups were not precisely
matched by age or sex. The in vitro data derived from
Figure 1 Regulation of interleukin (IL)-17 production in vitro. IL-
17A levels (pg/ml) measured by enzyme-linked immunosorbent
assay (ELISA) from supernatants taken from three different culture
conditions in healthy individuals. Calculated P values are from two-
tailed t-tests between IL-17 levels measured by ELISA from cultures
containing anti-CD3, anti-CD3 plus Th17 stimulatory conditions and
anti-CD3 plus Th17 stimulatory conditions with the addition of IL-4.
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the RA patient group is subject to selection bias due to
referral of refractory RA patients to a tertiary center,
and this is reflected in the greater prevalence of the V50
allele in this RA sample compared to previous results
[21]. The clinical measurements in our patients provide
a trend consistent with a previous report that the IL-4R
is an important severity gene in RA [21]. However, the
small sample size precludes any robust claims and
points to the need for additional large longitudinal stu-
dies of cohorts of patients with early RA.
One study has failed to confirm an association of the
I50V polymorphism with RA severity [26]. However,
Figure 2 Inhibition of interleukin (IL)-17 production by IL-4: effect of IL-4R genotype. (A) Healthy control group IL-17 measured by
enzyme-linked immunosorbent assay (ELISA) of culture supernatants. Comparison of Th17 conditions with or without IL-4: I/I, P = 0.0079; I/V, P =
0.0013; V/V, P = NS. Paired comparisons were performed using a two-tailed t-test. (B) Proportion of IL-17 inhibition by IL-4. Assuming 100% to be
the maximal IL-17 production (measured by ELISA) in supernatants of cultures containing anti-CD3 and Th17 stimulatory conditions, the
percentage change from baseline after the addition of IL-4 to cultures of peripheral blood mononuclear cells is shown. I, isoleucine; V, valine.
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Figure 3 Flow cytometric enumeration of Th17 cells following a 5-day culture of peripheral blood mononuclear cells (PBMCs).
(A) Representative flow cytometry histograms showing control PBMCs stained for CD4 and interleukin (IL)-17A after stimulation with anti-CD3,
anti-CD3 and Th17 stimulatory conditions and anti-CD3 and Th17 stimulatory conditions with IL4. Numbers in quadrants represent the
percentage of total cells expressing IL-17A. (B) Th17 and Th17/Th1 cell numbers generated in RA patient and control cultures. The difference
between each cell type was statistically significant, P < 0.05, comparing the patient and control groups. I, isoleucine; V, valine.
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this was a cross-sectional study in which participants
had radiographs performed after various durations of
RA. Severity was not calculated on the basis of the rate
of accumulation of joint damage over a specific interval
of time, and therefore an effect of I50V on severity may
have been overlooked.
The pattern of IL-17 suppression seen in the healthy
individuals was not replicated in the RA patients, poten-
tially because of confounding effects of the various med-
ications. A particularly interesting alternative (but not
mutually exclusive) explanation is that in established RA
Th17 cells become relatively refractory to IL-4, as we
have observed in established CIA [16]. To better assess
this possibility, it will be necessary to perform longitudi-
nal studies of IL-4R genotype and IL-4-mediated regula-
tion of IL-17 in a cohort of early-onset RA patients.
Allelic variation may lead to either gain or loss of
function through the IL-4R. Several prior studies have
found that receptors containing isoleucine at position
50, compared with receptors containing valine at the
same position, support increased signaling as measured
by signal transducer and transactivator 6 phosphoryla-
tion [21,27-29]. The precise mechanism for this effect is
not yet understood.
Although there is growing evidence for the impor-
tance of IL-4 in regulation of IL-17 production, the role
that IL-4 plays in controlling inflammation and bone
destruction extends beyond regulation of Th17 cells.
IL-4 is antiangiogenic [30], and intra-articular injections
of the IL-4 gene reduced synovial tissue vessel density,
inflammation and bone destruction in rat and mouse
models of arthritis [31,32]. IL-4 directly suppresses pro-
duction of vascular endothelial growth factor by synovial
fibroblasts [33]. It is not excluded, however, that some
of the in vivo effects of IL-4 on synovial angiogenesis
are due to inhibition of IL-17 production in the syno-
vium, with consequent downregulation of local produc-
tion of proangiogenic mediators.
Other studies have pointed to a direct role for IL-4 in
regulation of tissue destruction in arthritis. IL-4 inhibits
the spontaneous and stimulated production of matrix
metalloproteinase 1 by synoviocytes [34]. While IL-17 is
pro-osteoclastogenic in arthritis [35-37], IL-4 and IL-13
inhibit osteoclastic differentiation by activation of recep-
tors that decrease RANK formation and by activation of
receptors on osteoblasts that decrease RANKL expres-
sion but increase osteoprotegerin formation [36,38]. In
an animal model of osteoarthritis, intra-articular injec-
tion of IL-4 inhibits chondrocyte production of nitric
oxide and subsequent cartilage destruction [39]. IL-4
may also have suppressive effects on macrophage prolif-
eration [40] and cytokine production [41].
Conclusions
The data in the present study suggest that a SNP in IL-4R
confers a hypofunctional receptor that results in decreased
inhibition of IL-17 by IL-4, which may allow unrestricted
IL-17-mediated inflammation. IL-4 modulates inflamma-
tion and joint damage through various mechanisms,
including those discussed here, and an attractive topic for
future investigation is the effect of this SNP on the ability
of IL-4 to regulate pathogenic behavior of cells other than
CD4+ Th17 lymphocytes. Genotyping for V50 substitu-
tions in the IL-4R may help identify those patients who
are at the greatest risk for inflammation and tissue
destruction in RA and who would therefore be the most
suitable candidates for aggressive therapy, but this hypoth-
esis requires validation in a prospective study of early RA
patients. Approaches that regulate Th17 cells or neutralize
their products are under evaluation in the treatment of
RA and may be particularly attractive for patients in
whom endogenous mechanisms for control of Th17 cells
are demonstrably inadequate.
Additional material
Additional file 1: Table S1, Supplemental Figures S1 and S2. Table
S1. Baseline characteristics of study patients. Figure S1. Regulation of
interleukin-17 production in vitro. Figure S2. Inhibition of interleukin (IL)-
17 production by IL-4: effect of IL-4R genotype in rheumatoid arthritis
patients.
Figure 4 In vivo interleukin (IL)-17 production in healthy
individuals and RA patients. Comparison of control and RA serum
IL-17 levels, P = 0.05.
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